Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
1765–1800
Headlines
5751
Sources here
17
Companies here
24
Current section United States Medical Devices news

Chronological news

Earlier headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Earnings Flash (QDEL) QuidelOrtho Corporation Reports Q2 Revenue $630.9M, vs. FactSet Est of $618.7M

QuidelOrtho Corporation (QDEL) reported its Q2 revenue at $630.9 million, surpassing FactSet's estimate of $618.7 million. This announcement indicates stronger-than-expected financial performance for the company in the second quarter. The article also mentions recent changes in the company's indices and the appointment of a …

QDEL main company
Sharemaestro market context Price below Trend Line 52 weeks -48.7% QDEL stored weekly price path from 22 Aug 2025 to 14 Aug 2026

QT Imaging Holdings (QTI) director Timm Bryan files Form 3 showing no holdings

QT Imaging Holdings, Inc. director Timm Bryan has filed an initial Form 3, an SEC statement of beneficial ownership. The filing indicates no insider transactions, derivative positions, or reportable holdings in the company's securities for Bryan at the time of disclosure. This Form 3 …

QTI main company
Sharemaestro market context Stored weekly price path 29 weeks -49.1% · Next-week setup negative 38.9% QTI stored weekly price path from 30 Jan 2026 to 14 Aug 2026

TriSalus Life Sciences, Inc. 2026: Revenue $11.41M, EPS ($0.16) — 10-Q Summary

TriSalus Life Sciences, Inc. (TLSI) reported its 2026 quarterly results, showing revenue of $11.41M, which was nearly flat year-over-year, and a net loss of ($9.19M), resulting in a diluted loss per share of ($0.16). The company highlighted stable revenue, improved gross margin, continued commercial …

TLSI main company
Sharemaestro market context Price above Trend Line 52 weeks +4.4% TLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Sight Sciences, Inc. Stock 12‑Month Price Target Raised to $8.6, Implies 55% Upside

The average 12-month price target for Sight Sciences, Inc. (SGHT) stock has been raised from $8.4 to $8.6 by 5 analysts, with a range of $6 to $12 per share. This new target suggests a potential upside of approximately 55% based on the August …

SGHT main company
Sharemaestro market context Trend signal active 52 weeks +92.4% SGHT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Segall Bryant & Hamill LLC Acquires New Holdings in Tactile Systems Technology, Inc. $TCMD

Segall Bryant & Hamill LLC has acquired 49,382 shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD) worth approximately $1.29 million, indicating growing institutional interest in the company. Other institutional investors have also increased their stakes in TCMD, with 83.43% of the stock now owned by …

TCMD mentioned
Sharemaestro market context Trend signal active 52 weeks +82.9% TCMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Janus Henderson Group PLC Purchases 127,942 Shares of Tactile Systems Technology, Inc. $TCMD

Janus Henderson Group PLC increased its stake in Tactile Systems Technology, Inc. (TCMD) by 67.4% in the first quarter, acquiring an additional 127,942 shares to bring its total holdings to 317,695 shares valued at $8.3 million. Institutional investors now own 83.43% of the company, …

TCMD main company
Sharemaestro market context Trend signal active 52 weeks +82.9% TCMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Steris Posts Solid Q1 Results Amid Restructuring Plans

STERIS (STE) reported strong fiscal 2027 first-quarter results with 7% revenue growth and increased EPS, driven by its Healthcare segment and solid gains in Life Sciences and Applied Sterilization Technologies. The company announced a restructuring plan involving facility consolidations, incurring estimated charges of $55-70 …

STE main company
Sharemaestro market context Price above Trend Line 52 weeks -6.4% STE stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Sanuwave Announces Q2 FY2026 Financial Results

Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 2025. EDEN PRAIRIE, Minn., …

SNWV main company
Sharemaestro market context Price below Trend Line 52 weeks -89.5% · Next-week setup negative 41.6% SNWV stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Beyond Air regains Nasdaq bid-price compliance after 1-for-20 reverse split; discretionary monitor imposed

Beyond Air (XAIR) has regained compliance with Nasdaq's $1.00 bid-price rule following a 1-for-20 reverse stock split effected on July 13, 2026. The company maintained a closing bid price of $1.00 or greater for 17 consecutive trading days. Nasdaq has imposed a one-year Discretionary …

XAIR main company
Sharemaestro market context Price below Trend Line 52 weeks -86.0% · Next-week setup negative 35.9% XAIR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Form 8K Beyond Air Inc For: 6 August By Investing.com

This article from Investing.com reports on Beyond Air Inc.'s Form 8K filing for August 6th. The content primarily consists of market data, including various indices, commodities, currencies, and stock performance, but offers no further details on the specific contents of Beyond Air's filing. It …

XAIR main company
Sharemaestro market context Price below Trend Line 52 weeks -86.0% · Next-week setup negative 35.9% XAIR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Hyperfine Q2 2026 earnings: Revenue rises 45% as operating loss narrows

Hyperfine (Nasdaq: HYPR) reported a 44.8% increase in Q2 2026 revenue, reaching $3.904 million, with commercial Swoop system sales rising and gross margin expanding, which helped narrow the operating loss. Despite operational improvements, the net loss remained nearly flat at $9.298 million due to …

HYPR main company
Sharemaestro market context Price below Trend Line 52 weeks -31.1% HYPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Artivion (NYSE:AORT) Delivers Strong Q2 CY2026 Numbers

Artivion (NYSE:AORT) reported strong Q2 CY2026 results, with revenue of $125.8 million, beating analyst estimates by 4.4%, and non-GAAP EPS of $0.13, exceeding estimates by 34.5%. The medical device company reconfirmed its full-year revenue guidance and provided optimistic EBITDA guidance. Despite a decrease in …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

electroCore Announces Second Quarter 2026 Financial Results

electroCore announced strong second-quarter 2026 financial results, with net sales increasing by 28% to $9.5 million, driven by growth in U.S. prescription sales and Truvaga sales. The company reduced its net loss by 17% and improved Adjusted EBITDA by 26% year-over-year. electroCore also raised …

ECOR main company
Sharemaestro market context Trend signal started 52 weeks +77.4% ECOR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

[10-Q] electroCore, Inc. Quarterly Earnings Report

electroCore, Inc. (ECOR) filed its quarterly earnings report (Form 10-Q) for the period ending June 30, 2026, revealing funding shortfalls and raising substantial doubt about its ability to continue as a going concern. The company reported a net loss of $8.3 million for the …

ECOR main company
Sharemaestro market context Trend signal started 52 weeks +77.4% ECOR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Artivion: Q2 Earnings Snapshot

Artivion, Inc. (AORT) reported a second-quarter loss of $13.5 million, or 28 cents per share, which contrasts with a profit in the same period last year. Adjusted earnings for the biological medical device maker were 13 cents per share, with revenue reaching $130.8 million. …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Earnings Flash (AORT) Artivion, Inc. Reports Q2 Revenue $125.8M, vs. FactSet Est of $120.0M

Artivion, Inc. (AORT) has reported its Q2 revenue of $125.8 million, surpassing FactSet's estimate of $120.0 million. This earnings flash indicates a positive financial performance for the medical device company. The news was published on August 6, 2026, at 05:07 pm EDT.

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Outset Medical Inc. (OM) Misses Q2 EPS by 5c

Outset Medical Inc. (OM) reported its Q2 earnings, missing analyst estimates for EPS by $0.05, with an EPS of ($0.80) against an anticipated ($0.75). Despite the EPS miss, the company slightly exceeded revenue expectations, bringing in $31.6 million compared to the consensus estimate of …

OM main company
Sharemaestro market context Trend signal active 52 weeks -68.2% · Next-week setup negative 42.8% OM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Globus Medical Reports Second Quarter 2026 Results

Globus Medical AUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026. Second Quarter 2026: Worldwide net sales were $789.6 million, an increase …

GMED main company
Sharemaestro market context Price above Trend Line 52 weeks +37.4% GMED stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results

Senseonics Holdings, Inc. announced strong second-quarter 2026 financial results, with revenue growing approximately 120% year-over-year to $14.5 million and gross margin reaching 59%. The company raised its full-year 2026 revenue guidance to $62 million to $66 million and gross margin guidance to 58% to …

SENS main company
Sharemaestro market context New activity signal 52 weeks -14.6% · Next-week setup negative 44.2% SENS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Sight Sciences Inc (SGHT) (Q2 2026) Earnings Call Highlights: Record Revenue Growth and Raised ...

Sight Sciences Inc. (SGHT) reported strong Q2 2026 earnings, featuring a 20% year-over-year increase in total revenue to $23.4 million, marking its strongest quarterly growth in three years. The company also saw significant improvement in its interventional dry eye revenue, which nearly doubled, and …

SGHT main company
Sharemaestro market context Trend signal active 52 weeks +92.4% SGHT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AVITA Medical Q2 revenue rises 18% to $21.7M; raises 2026 guidance, expects Q4 cash-flow breakeven

AVITA Medical reported strong Q2 2026 financial results with revenue increasing 18% year-over-year to $21.7 million, driven by the success of RECELL, Cohealyx, and PermeaDerm. The company narrowed its net loss and raised its full-year 2026 revenue guidance to $86-$89 million, projecting cash-flow breakeven …

RCEL main company
Sharemaestro market context Trend signal active 52 weeks +60.9% · Next-week setup negative 36.1% RCEL stored weekly price path from 22 Aug 2025 to 14 Aug 2026

iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm Holdings, Inc. announced its definitive agreement to acquire VitalConnect for approximately $287.5 million, comprising cash and iRhythm common stock. This acquisition is expected to broaden iRhythm's cardiac monitoring platform by adding mobile cardiac telemetry and multi-vitals monitoring capabilities, expanding its addressable market across …

IRTC main company
Sharemaestro market context Price above Trend Line 52 weeks -25.2% IRTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Accuray Announced Transfer or Voluntary Withdrawal of Listing

Accuray (ARAY) has received Nasdaq approval to transfer its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective August 6, 2026. The company retains its ARAY symbol and has an additional 180 days, until February 1, 2027, to …

ARAY main company
Sharemaestro market context Price below Trend Line 52 weeks -82.5% · Next-week setup negative 43.7% ARAY stored weekly price path from 22 Aug 2025 to 14 Aug 2026

908 Devices Inc. (MASS) holder AWM sells 50,000 shares, keeps 4.83M

AWM Investment Company, Inc., a ten percent owner of 908 Devices Inc. (MASS), indirectly sold 50,000 shares of Common Stock on August 4, 2026, at a weighted average price of $8.3553 per share. Following this transaction, AWM's aggregate holdings through advised limited partnerships amount …

MASS main company
Sharemaestro market context Trend signal active 52 weeks +55.2% MASS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

Apyx Medical Corporation reported its second-quarter 2026 financial results, with total revenue of $13.9 million, primarily driven by a 28% growth in its Surgical Aesthetics segment. The company reaffirmed its full-year 2026 revenue guidance of $59.0 million to $60.0 million and highlighted the successful …

APYX main company
Sharemaestro market context Trend signal ended 52 weeks +45.0% APYX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Apyx Medical Reports Q2 2026 Revenue of $13.9M, Surgical Aesthetics Up 28%

Apyx Medical announced its Q2 2026 financial results, reporting total revenue of $13.9 million, a 22% year-over-year increase, largely driven by a 28% growth in its Surgical Aesthetics segment. Despite a GAAP net loss of $3.2 million and an adjusted EBITDA loss of $0.7 …

APYX main company
Sharemaestro market context Trend signal ended 52 weeks +45.0% APYX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Apyx Medical’s AYON System Gains FDA 510(k) Clearance for Power Liposuction

Apyx Medical reported Q2 2026 revenue of $13.9 million, a 22% year-over-year increase, primarily driven by 28% growth in its Surgical Aesthetics segment. The company also announced expanded FDA 510(k) clearance for its AYON Body Contouring System to include power liposuction and reaffirmed its …

APYX main company
Sharemaestro market context Trend signal ended 52 weeks +45.0% APYX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Lazard Asset Management LLC Buys New Holdings in Beta Bionics, Inc. $BBNX

Lazard Asset Management LLC has acquired a new stake of 71,905 shares in Beta Bionics (NASDAQ:BBNX), valued at approximately $720,000, representing 0.16% ownership. Other institutional investors also established or increased positions in the company. Beta Bionics shares recently traded down 4.5% at $13.91, with …

BBNX main company
Sharemaestro market context Trend signal active 52 weeks +3.0% BBNX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Delcath Systems (NASDAQ:DCTH) Price Target Raised to $21.00 at BTIG Research

BTIG Research has raised its price target for Delcath Systems (NASDAQ:DCTH) to $21.00 from $17.00, maintaining a "Buy" rating and implying a 40% upside. This follows Delcath's strong quarterly performance, where it exceeded revenue and EPS expectations. The stock surged 18.8% to $15.00 on …

DCTH main company
Sharemaestro market context Trend signal active 52 weeks +50.4% DCTH stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Profound Medical (NASDAQ: PROF) boosts revenue 62% while cutting loss

Profound Medical Corp. (NASDAQ: PROF) announced a significant revenue increase of 62% for the six months ended June 30, 2026, reaching $7.82 million, primarily due to higher capital equipment sales and recurring non-capital revenue. The company also narrowed its net loss to $16.59 million …

PROF main company
Sharemaestro market context Trend signal active 52 weeks +39.9% PROF stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context